Published in Arterioscler Thromb Vasc Biol on October 24, 2013
PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity. J Lipid Res (2014) 0.88
The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol (2015) 0.80
AMP-Activated Protein Kinase Interacts with the Peroxisome Proliferator-Activated Receptor Delta to Induce Genes Affecting Fatty Acid Oxidation in Human Macrophages. PLoS One (2015) 0.78
Hematopoietic knockdown of PPARδ reduces atherosclerosis in LDLR-/- mice. Gene Ther (2015) 0.75
Peroxisome proliferator activated receptor-δ: the middle child vies for attention. Arterioscler Thromb Vasc Biol (2014) 0.75
PPARβ/δ selectively regulates phenotypic features of age-related macular degeneration. Aging (Albany NY) (2016) 0.75
Niacin promotes revascularization and recovery of limb function in diet-induced obese mice with peripheral ischemia. Pharmacol Res Perspect (2016) 0.75
Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell. Inflammation (2016) 0.75
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
The genome of the pear (Pyrus bretschneideri Rehd.). Genome Res (2012) 2.55
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology (2006) 2.43
Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res (2005) 2.41
Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem (2007) 2.27
Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology (2009) 2.18
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol (2008) 2.11
Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat Biotechnol (2011) 2.01
Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. Circ Cardiovasc Genet (2011) 1.78
Polygenic determinants of severe hypertriglyceridemia. Hum Mol Genet (2008) 1.77
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood (2011) 1.77
Adenylyl cyclase isoform-selective regulation of vascular smooth muscle proliferation and cytoskeletal reorganization. Circ Res (2006) 1.76
Water clusters in nonpolar cavities. Proc Natl Acad Sci U S A (2004) 1.59
Lipid incorporation inhibits Src-dependent assembly of fibronectin and type I collagen by vascular smooth muscle cells. Circ Res (2009) 1.56
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol (2007) 1.56
Quantum teleportation and entanglement distribution over 100-kilometre free-space channels. Nature (2012) 1.56
APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med (2008) 1.52
A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet (2009) 1.49
Polyploidy impairs human aortic endothelial cell function and is prevented by nicotinamide phosphoribosyltransferase. Am J Physiol Cell Physiol (2009) 1.45
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics (2007) 1.39
Vascular smooth muscle cells orchestrate the assembly of type I collagen via alpha2beta1 integrin, RhoA, and fibronectin polymerization. Am J Pathol (2003) 1.37
Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes (2009) 1.36
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A (2014) 1.30
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics (2011) 1.24
Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. Cardiovasc Diabetol (2008) 1.23
Pharmacogenomics of the OATP and OAT families. Pharmacogenomics (2004) 1.21
Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation. Arterioscler Thromb Vasc Biol (2010) 1.21
Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem (2005) 1.19
Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther (2003) 1.16
Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J Biol Chem (2006) 1.15
CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat (2013) 1.13
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res (2006) 1.12
Two new coumarins from Micromelum falcatum with cytotoxicity and brine shrimp larvae toxicity. Molecules (2012) 1.08
SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Lett (2009) 1.07
NAD(+), sirtuins, and cardiovascular disease. Curr Pharm Des (2009) 1.07
Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player. Curr Opin Lipidol (2013) 1.06
Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res (2009) 1.04
Role of hepatic resident and infiltrating macrophages in liver repair after acute injury. Biochem Pharmacol (2013) 1.04
Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res (2008) 1.04
Functional linkage between the endoplasmic reticulum protein Hsp47 and procollagen expression in human vascular smooth muscle cells. J Biol Chem (2002) 1.03
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics (2008) 1.03
Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proc Natl Acad Sci U S A (2013) 1.03
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos (2007) 1.02
Antiatherogenic properties of flavonoids: implications for cardiovascular health. Can J Cardiol (2010) 1.02
Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg (2007) 1.02
Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry (2003) 1.01
The functional consequence of RhoA knockdown by RNA interference in rat cerebral arteries. Am J Physiol Heart Circ Physiol (2007) 1.00
Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell (2009) 0.99
An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler Thromb Vasc Biol (2011) 0.99
Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. Arterioscler Thromb Vasc Biol (2002) 0.99
Directed differentiation of skin-derived precursors into functional vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2011) 0.99
Experimental long-distance decoy-state quantum key distribution based on polarization encoding. Phys Rev Lett (2007) 0.98
Differential Lipotoxic Effects of Palmitate and Oleate in Activated Human Hepatic Stellate Cells and Epithelial Hepatoma Cells. Cell Physiol Biochem (2016) 0.98
Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample. BMC Med Genet (2007) 0.98
Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology (2009) 0.98
Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice. J Lipid Res (2012) 0.98
Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. J Lipid Res (2002) 0.98
Alkaloids from the stem bark of Micromelum falcatum. Chem Pharm Bull (Tokyo) (2009) 0.96
Apolipoprotein C-III: going back to the future for a lipid drug target. Circ Res (2013) 0.96
[Investigation on the changes of dependent signal on the amplitude of low frequency fluctuations at blood oxygen level in brain after acupuncture Neiguan (PC 6)]. Zhongguo Zhen Jiu (2009) 0.96
Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. Circ Res (2013) 0.95
The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Fibroblast growth factor-2 and remodeled type I collagen control membrane protrusion in human vascular smooth muscle cells: biphasic activation of Rac1. J Biol Chem (2004) 0.95
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet (2013) 0.95
A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol (2007) 0.94
Citrus flavonoids and lipid metabolism. Curr Opin Lipidol (2013) 0.94
Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes (2011) 0.94
Lord of the rings--the mechanism for oxidosqualene:lanosterol cyclase becomes crystal clear. Trends Pharmacol Sci (2005) 0.94
MicroRNA-1 inhibits myocardin-induced contractility of human vascular smooth muscle cells. J Cell Physiol (2010) 0.94
Water between plates in the presence of an electric field in an open system. J Phys Chem B (2005) 0.93
ATP-binding cassette transporter A1 expression and apolipoprotein A-I binding are impaired in intima-type arterial smooth muscle cells. Circulation (2009) 0.92
Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol (2010) 0.92